NRX Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $0 | $0 | — | — |
| Operating income | -$16.2M | -$18.5M | -$27.8M | -$44.3M | -$115.8M |
| Operating expenses | — | $18.5M | $27.8M | $44.3M | $115.8M |
| Cost of revenue | $505,000 | $0 | — | — | — |
| Cash from operations | -$14.1M | -$10.6M | -$21.7M | -$39.8M | -$37.7M |
| Capital expenditure | — | $0 | $3,000 | $10,000 | $7,000 |
| Free cash flow | — | -$10.6M | -$21.7M | -$39.8M | -$37.7M |
| Impairments | $0 | $0 | — | — | — |
| Total assets | $13.0M | $3.7M | $7.3M | $25.8M | $32.7M |
| Total liabilities | $28.9M | $26.9M | $19.0M | $18.4M | $11.9M |
| Total debt | — | — | $11.0M | $11.0M | — |
Shares outstanding 36.2M · Free float 11.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.